Literature DB >> 19247306

The FGF family: biology, pathophysiology and therapy.

Andrew Beenken1, Moosa Mohammadi.   

Abstract

The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacological potential of this family. This Review discusses traditional applications of recombinant FGFs and small-molecule FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphataemic diseases.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19247306      PMCID： PMC3684054          DOI： 10.1038/nrd2792

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  277 in total

1.  An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release.

Authors:  A Aigner; M Butscheid; P Kunkel; E Krause; K Lamszus; A Wellstein; F Czubayko
Journal:  Int J Cancer       Date:  2001-05-15       Impact factor: 7.396

2.  Male-to-female sex reversal in mice lacking fibroblast growth factor 9.

Authors:  J S Colvin; R P Green; J Schmahl; B Capel; D M Ornitz
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

3.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Authors:  Tobias Larsson; Xijie Yu; Siobhan I Davis; Mohamad S Draman; Sean D Mooney; Michael J Cullen; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

4.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease.

Authors:  B Schumacher; P Pecher; B U von Specht; T Stegmann
Journal:  Circulation       Date:  1998-02-24       Impact factor: 29.690

5.  Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.

Authors:  E F Unger; L Goncalves; S E Epstein; E Y Chew; C B Trapnell; R O Cannon; A A Quyyumi
Journal:  Am J Cardiol       Date:  2000-06-15       Impact factor: 2.778

6.  Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Authors:  Shohei Nakanishi; Junichiro James Kazama; Tomoko Nii-Kono; Kentaro Omori; Takeyoshi Yamashita; Seiji Fukumoto; Fumitake Gejyo; Takashi Shigematsu; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

7.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

8.  Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Authors:  Thomas J Weber; Shiguang Liu; Olafur S Indridason; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

9.  Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

Authors:  M A Eisenberger; L M Reyno; D I Jodrell; V J Sinibaldi; K H Tkaczuk; R Sridhara; E G Zuhowski; M H Lowitt; S C Jacobs; M J Egorin
Journal:  J Natl Cancer Inst       Date:  1993-04-21       Impact factor: 13.506

10.  Liver-specific activities of FGF19 require Klotho beta.

Authors:  Benjamin C Lin; Manping Wang; Craig Blackmore; Luc R Desnoyers
Journal:  J Biol Chem       Date:  2007-07-11       Impact factor: 5.157
View more
  637 in total

1.  The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo.

Authors:  Maria S Aguzzi; Debora Faraone; Daniela D'Arcangelo; Francesco De Marchis; Gabriele Toietta; Domenico Ribatti; Alberto Parazzoli; Paolo Colombo; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

3.  FGF-dependent regulation of VEGF receptor 2 expression in mice.

Authors:  Masahiro Murakami; Loc T Nguyen; Kunihiko Hatanaka; William Schachterle; Pei-Yu Chen; Zhen W Zhuang; Brian L Black; Michael Simons
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

4.  Aryl Extensions of Thienopyrimidinones as Fibroblast Growth Factor Receptor 1 Kinase Inhibitors.

Authors:  Anil R Ekkati; Valsan Madiyan; Krishna P Ravindranathan; Jae H Bae; Joseph Schlessinger; William L Jorgensen
Journal:  Tetrahedron Lett       Date:  2011-04-27       Impact factor: 2.415

5.  Pten loss induces autocrine FGF signaling to promote skin tumorigenesis.

Authors:  Kristina Hertzler-Schaefer; Grinu Mathew; Ally-Khan Somani; Sunil Tholpady; Madhavi P Kadakia; Yiping Chen; Dan F Spandau; Xin Zhang
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

6.  Therapeutic effects of fibroblast growth factor-10 on hyperoxia-induced bronchopulmonary dysplasia in neonatal mice.

Authors:  Tao Han; Ming Chi; Yan Wang; Yabo Mei; Qiuping Li; Mengnan Yu; Qianqian Ma; Yuhan Chen; Zhichun Feng
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  Small Peptide Modulation of Fibroblast Growth Factor Receptor 3-Dependent Postnatal Lymphangiogenesis.

Authors:  David P Perrault; Gene K Lee; Sun Young Park; Sunju Lee; Dongwon Choi; Eunson Jung; Young Jin Seong; Eun Kyung Park; Cynthia Sung; Roy Yu; Antoun Bouz; Austin Pourmoussa; Soo Jung Kim; Young-Kwon Hong; Alex K Wong
Journal:  Lymphat Res Biol       Date:  2019-01-16       Impact factor: 2.589

8.  Gas-Phase Analysis of the Complex of Fibroblast GrowthFactor 1 with Heparan Sulfate: A Traveling Wave Ion Mobility Spectrometry (TWIMS) and Molecular Modeling Study.

Authors:  Yuejie Zhao; Arunima Singh; Yongmei Xu; Chengli Zong; Fuming Zhang; Geert-Jan Boons; Jian Liu; Robert J Linhardt; Robert J Woods; I Jonathan Amster
Journal:  J Am Soc Mass Spectrom       Date:  2016-09-23       Impact factor: 3.109

9.  Acromegaly is associated with high fibroblast growth factor-21 levels.

Authors:  B S Yurekli; N O Kutbay; M Aksit; A Suner; I Y Simsir; S Seckiner; G U Kocabas; G Bozkaya; F Saygili
Journal:  J Endocrinol Invest       Date:  2018-05-12       Impact factor: 4.256

Review 10.  Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis.

Authors:  Lucas D BonDurant; Matthew J Potthoff
Journal:  Annu Rev Nutr       Date:  2018-05-04       Impact factor: 11.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.